publication venue for
- Author Correction: Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. 2023
- Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies. 2024
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial. 2024
- Loss of Pip4k2c confers liver-metastatic organotropism through insulin-dependent PI3K-AKT pathway activation. 2024
- Imetelstat-mediated alterations in fatty acid metabolism to induce ferroptosis as a therapeutic strategy for acute myeloid leukemia. 2023
- Systematic evaluation of AML-associated antigens identifies anti-U5 SNRNP200 therapeutic antibodies for the treatment of acute myeloid leukemia. 2023
- Immunotargeting of a recurrent AML-specific neoantigen.. 4. 2023
- Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.. 4. 2023
- Breathing room - focusing on the 'other' lung cancer.. 4. 2023
- WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. 2023
- ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. 2023
- Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer. 2023
- CAR T cell therapy: looking back and looking forward.. 3. 2022
- cfDNA methylome profiling for detection and subtyping of small cell lung cancers.. 3. 2022
- Multimodal data integration using machine learning improves risk stratification of high-grade serous ovarian cancer.. 3. 2022
- SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes.. 3. 2022
- Astrocytic laminin-211 drives disseminated breast tumor cell dormancy in brain.. 3. 2021
- Challenges and opportunities in 2021.. 2. 2021
- Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism.. 2. 2021
- Proteogenomics of non-small cell lung cancer reveals molecular subtypes associated with specific therapeutic targets and immune evasion mechanisms.. 2. 2021
- Radiation-activated secretory proteins of Scgb1a1+ club cells increase the efficacy of immune checkpoint blockade in lung cancer.. 2. 2021
- Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma.. 2. 2021
- ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer.. 2. 2021
- FATTY ACID SYNTHESIS IS REQUIRED FOR BREAST CANCER BRAIN METASTASIS.. 2. 2021
- EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer.. 2. 2021
- Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors.. 2. 2021
- FYN-TRAF3IP2 induces NF-κB signaling-driven peripheral T cell lymphoma.. 2. 2021
- Accelerating precision medicine in metastatic prostate cancer.. 1. 2020
- Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets.. 1. 2020
- Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy.. 1. 2020
- Multi-omic analysis reveals significantly mutated genes and DDX3X as a sex-specific tumor suppressor in cutaneous melanoma.. 1. 2020
- The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing.. 1. 2020
- Single-cell RNA sequencing reveals compromised immune microenvironment in precursor stages of multiple myeloma.. 1. 2020
- Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors.. 1. 2020
- Direct genome editing of patient-derived xenografts using CRISPR-Cas9 enables rapid in vivo functional genomics.. 1. 2020
- L1CAM defines the regenerative origin of metastasis-initiating cells in colorectal cancer.. 1. 2020
- Breaking up MTDH-SND1 to break down metastasis. 2022
- A quick guide for clinical oncology. 2021
- Dysregulation and therapeutic targeting of RNA splicing in cancer. 2022